PharmaVentures increases life science presence in the USA
OXFORD, England, February 11th 2015. PharmaVentures is pleased to announce that it is to increase its life science presence in North America by establishing a new base in Boston, MA. Starting this month Dr Adrian Dawkes, VP, will be dividing his time between the USA...
Client News Update: Novartis enters exclusive talks on the potential sale of its UK Horsham site to the University of Brighton
OXFORD, UK, January 27th, 2015. PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015. The University...
PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain
Pharma licensing agreement.
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.
PharmaVentures becomes latest Partner of One Nucleus
PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally.
PharmaVentures Acts As Advisor to Plethora Solutions in deal with Recordati
OXFORD, UK, October 1st, 2014 PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature...
PharmaVentures increases its Asia-Pacific presence
OXFORD, UK, September 24th, 2014 PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. Aki has been involved in over 18 start-up or...
PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease
PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential…
PharmaVentures strengthens its expertise in early stage deal making
PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi’s R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010…
PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health
PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June…
PharmaVentures Divests Manufacturing Facility for Major Pharma Client
PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May,…
PharmaVentures expands reach to Latin America
PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. A dynamic professional with formal education in…
PharmaVentures engaged in valuation of assets for newly AIM listed Tiziana Life Sciences.
PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it’s successful admission onto London Stock Exchange’s AIM in April 2014.
Tiziana Life Sciences, is a London…
Novartis appoints PharmaVentures as advisors on the future of its UK Horsham site
PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. These options could include reusing part of the site as a science or business park, thereby creating a legacy with the possibility…
PharmaVentures Strengthens M&A Team
PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space.
Over the last 30 years, Nigel has worked…
PharmaVentures advised Nanosight on its sale to Spectris plc.
PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.
PharmaVentures advised Dogu Tip on its sale to Gulf Capital
PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive…
PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding
PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi’s divestment of its Zentiva subsidiary’s production plant in Hlohovec, Slovakia.
Stephen Waterman joins PharmaVentures
Oxford, UK, October 18th, 2012 PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare...